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Background: Cell-free DNA (cfDNA) circulating in the blood holds a possible prognostic value in malignant diseases. Under
malignant conditions, the level of cfDNA increases but the biological mechanism remains to be fully understood. We aimed to
examine the correlation between cfDNA and total tumour burden defined by positron emission tomography (PET) parameters.
Methods: Patients with advanced non-small cell lung cancer (NSCLC) were enrolled into a prospective biomarker trial. Before
treatment, plasma was extracted and the level of cfDNA was determined by qPCR. An 18F-fluorodeoxyglucose (18F-FDG)
PET/computed tomography (CT) scan was performed and evaluated in terms of metabolic tumour volume (MTV) and total lesion
glycolysis (TLG). Tumour contours were delineated semi-automatically by a threshold standardised uptake value (SUV) of 2.5.
The primary end point was correlation among cfDNA, MTV and TLG. The secondary end point was overall survival (OS) according
to cfDNA, MTV and TLG.
Results: Fifty-three patients were included. There were no correlations between cfDNA and MTV (r¼ 0.1) or TLG (r¼ 0.1). cfDNA
475th percentile was correlated with shorter OS (P¼ 0.02), confirmed in a multivariate analysis. MTV4the median was associated
with a significantly shorter OS (P¼ 0.02). There was no significant difference in OS according to TLG (P¼ 0.08).
Conclusion: Cell-free DNA may not be a simple measure of tumour burden, but seems to reflect more complex mechanisms
of tumour biology, making it attractive as an independent prognostic marker.
Lung cancer is one of the most common cancers worldwide and
associated with considerable morbidity and mortality. The choice
of treatment is based on the extent of disease at the time of
diagnosis. In non-small cell lung cancer (NSCLC), patients with
localised disease may be offered curatively intended surgery or
chemo-radiotherapy, whereas patients with advanced disease are
treated with chemotherapy and/or biological drugs in a palliative
setting (Rinaldi et al, 2006; Gorenstein and Sonett, 2011; Mok et al,
2012). The treatment is often associated with side effects and the
long-term survival is poor. During recent years, individualised
treatment strategies have gained an increasing interest. The
possibility of targeting the treatment and thereby avoiding
unnecessary toxicity and hopefully increasing the treatment
response is attractive, but it requires mapping of the tumour
biology. One way of gaining further information about the tumour
is by using tumour markers. Many different markers have been and
are currently investigated, but so far only few have proved to be
clinically useful (Vadakara and Borghaei, 2012).
One potential marker is cell-free DNA (cfDNA), which are
small fragments of DNA detectable in the blood (Leon et al, 1977).
Several studies suggest that cfDNA is shed by both normal cells
and tumour cells, making it potentially attractive as an easily
accessible source of information on tumour biology. During
malignant conditions, the level of cfDNA is believed to increase
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due to increased release from the tumour cells, and possibly also
from normal cells in the tumour surrounding tissue. The biological
mechanisms behind the increased release remain to be fully
understood, but elements of apoptosis, necrosis, especially of large
tumours, and the possibility of active release from the tumour have
been presented (Stroun et al, 2000). Several studies have
demonstrated a prognostic value of the level of cfDNA in different
malignancies (De et al, 2011; De Mattos-Arruda et al, 2011;
Ellinger et al, 2011; Punnoose et al, 2012; Schwarzenbach et al,
2011; Spindler et al, 2012; Dawson et al, 2013). These observations
have led to the question of whether the increased level of cfDNA
merely represents an increased tumour burden, or whether other
biological mechanisms associated with the aggressiveness of the
tumour are involved. It seems to be plausible that more aggressive
tumours cause higher levels of cfDNA, thereby impairing the
prognosis, but further investigations addressing this issue are
needed.
During the disease staging process, many of the patients with
NSCLC have functional imaging performed with positron emission
tomography/computed tomography (PET/CT), using 18F-fluoro-
deoxyglucose (18F-FDG), which enables estimation of volume-
based parameters such as the metabolic tumour volume (MTV)
and the total lesion glycolysis (TLG) (Gould et al, 2001). The first
estimate (MTV) is a purely volumetric entity, while TLG also takes
the metabolic activity of the lesion into account, thereby providing
an estimate of the tumour activity. Hence, PET parameters provide
a means of estimating the tumour burden and also, to some
extent, the metabolic activity and aggressiveness of the disease.
A prognostic value of either whole-body or primary tumour MTV
and TLG in NSCLC has previously been demonstrated with higher
values correlating with shorter progression-free survival (PFS) and
overall survival (OS) (Lee et al, 2007; Chen et al, 2012; Kim et al,
2012; Liao et al, 2012; Zaizen et al, 2012; Zhang et al, 2012, 2013;
Hyun et al, 2013).
The aim of our study was to investigate the correlation between
the baseline level of cfDNA and volumetric parameters of the
PET/CT scan, and to evaluate the prognostic value of cfDNA and
the PET parameters.
MATERIALS AND METHODS
Patients. During a 3-year period (2007–2010), patients with newly
diagnosed advanced NSCLC referred for first-line chemotherapy
were enrolled into a prospective biomarker trial at the Department
of Oncology, Vejle Hospital, Denmark as previously presented
(Nygaard, 2012). The inclusion criteria comprised histopathologi-
cally confirmed NSCLC stage III or IV, no previous chemotherapy,
performance status (PS) p2 and age above 18 years. All patients
had a pre-treatment peripheral blood sample drawn from which
plasma was isolated and stored at  80 1C. Patients were
subsequently treated with standard first-line chemotherapy
comprising carboplatin (dose based on AUC5, given i.v. on day
1 every 3 weeks) in combination with vinorelbine (30mgm 2
given i.v. on day 1 every 3 weeks and 60mgm 2 p.o. day 8 every
3 weeks) for a maximum of six cycles. One patient was additionally
treated with bevacizumab in combination with the chemotherapy.
Palliative radiotherapy was given if indicated.
When indicated, the routine staging was supplemented by a
PET-CT scan. The PET scan was evaluated in terms of whole-body
MTV and TLG by a dedicated nuclear medicine specialist, blinded
to the level of cfDNA. Only patients with a PET/CT scan within a
month before blood sampling were included in the present study.
All patients had a baseline CT of the chest and upper abdomen
within a month before treatment start. Control CT scans were
performed after every two treatment cycles and every 3 months
after finishing chemotherapy, or earlier when indicated. Objective
response was evaluated according to RECIST v.1.0 (Therasse et al,
2000). The primary end point was correlation between the baseline
level of cfDNA and tumour burden estimated by whole-body MTV
and TLG. The secondary end points were PFS and OS according to
the level of MTV, TLG and cfDNA.
Written informed consent was obtained before enrolment. The
study was approved by the Regional Scientific Ethical Committee
for Southern Denmark in accordance with Danish law.
The REMARK criteria were considered and applied whenever
possible (McShane et al, 2005).
Analysis of cfDNA. Plasma was obtained from a pre-treatment
peripheral 10ml EDTA-blood sample by centrifugation at 2000 g
for 10min, and stored at  80 1C. The plasma was prepared within
2 h after sampling. Total nucleic acid was obtained from 1.0ml
plasma by the use of a QIAsymphony virus/bacteria midi-kit on a
QIAsymphony robot (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. Analyses of total number of cfDNA
alleles were performed by an in-house developed method targeting
the peptidylprolyl isomerase A (PPIA) gene as described and
validated previously (Steffensen et al, 2011; Spindler et al, 2012).
PET/CT imaging and image analysis. The PET scans were
performed using a GEMINI TF/16 channel PET/CT scanner
(Philips Medical Systems, Cleveland, OH, USA). An average of
310MBq (271–405MBq) of 18F-FDG was injected intravenously.
Images were obtained 1 h after injection of the tracer covering
from the base of the skull to the upper thigh with 2min per bed
position. The patient preparation was in accordance with the
EANM procedure guideline (Boellaard et al, 2010). Images were
reconstructed with the Philips reconstruction protocol: Body-
CTAC-NAC (LOR-based OSEM with TOF; iterations: 3; subsets: 33).
Images were analysed on a Philips Extended Brilliance Workspace
(Philips Healthcare, Best, The Netherlands), v. 4.5.3.40140 using the
Tumour Tracking software. All scans were attenuation corrected with a
low-dose CT (50mAs, 120kV, slice thickness 5mm, increment 2.5mm,
pitch 0.81, collimation 16 1.5mm). The patient’s baseline, iv contrast
enhanced, high-dose CT images were also used when evaluating the
PET/CT. The 18F-FDG uptake was assessed using the standardised
uptake value (SUV), which normalises the radioactivity measured in
tissue by the injected dose and the body weight of the patient. Three-
dimensional volumes of interest (VOIs) were calculated automatically
for all tumour lesions using the ‘bounded brick’ tool with a threshold of
2.5 SUV including primary tumour, lymph nodes and metastases. If the
VOIs included physiological FDG uptake, then they were manually
corrected using the ‘interactive’ tool. Volumes of interest were created by
an experienced nuclear medicine PET/CT specialist blinded to the level
of cfDNA. Each patient had a MTV calculated as the sum of each VOI.
For each lesion volume and SUV mean was multiplied and then
summed to generate the TLG.
Statistics. Correlations between patient characteristics and
cfDNA, MTV and TLG were analysed by the Wilcoxon rank-
sum test. The correlation between the level of cfDNA, MTV and
TLG was determined by the non-parametric Spearman’s rank
correlation method. Survival data were analysed by the Kaplan–
Meier method, and differences between the groups were estimated
by the log-rank test.
Objective response was determined according to the RECIST 1.0
criteria.
Progression-free survival was defined as time elapsed between
the first day of treatment and date of progression or death from
any cause. Overall survival was defined as time between the
first day of treatment and date of death from any cause. Patients
who did not experience any event were censored by 1
November 2012.
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The independent effect of different variables was investigated in
multivariate Cox regression analysis. Known prognostic variables
and the variables of interest in the study (cfDNA, MTV and TLG)
were included in the model.
All statistics were carried out in the NCSS statistical software
(NCSS Statistical Software, Kaysville, UT, USA; version 07.1.15,
2009). Two-sided P-values o0.05 were considered as significant.
RESULTS
Patients. Fifty-three patients fulfilled the criterion of a PET/CT
scan within a month (median 13 days) before the blood sampling
and were included in the study. Patient characteristics are listed in
Table 1. The level of cfDNA, whole-body MTV and TLG was
determined in all patients. The level of cfDNA ranged from 450 to
133 800 alleles per ml with a median of 2200. The median whole-
body MTV was 95ml (range 3–647) and the median TLG was 444
(range 12–4435).
The correlation between patient characteristics and cfDNA and
PET parameters was investigated and revealed a significantly lower
TLG in patients with adenocarcinomas compared with patients
with squamous cell carcinoma. There were no other significant
correlations.
Correlation between MTV, TLG and cfDNA. As demonstrated
in Figure 1, there was no correlation between the level of cfDNA
and MTV (correlation coefficient r¼ 0.1). Likewise, no correlation
between the level of cfDNA and TLG was detected (r¼ 0.1). On the
other hand, there was an almost perfect correlation between MTV
and TLG (r¼ 0.97).
Survival analyses. The median PFS was 5.9 months (95% CI 5.6–7.1)
and the median OS was 15.7 months (95% CI 10.8–21.8). Survival
data were further analysed according to the levels of cfDNA, MTV
and TLG. To determine the most appropriate cutoff, all of the three
parameters were divided into quartiles. This exploratory approach
revealed a significantly shorter OS of patients with cfDNA in the
upper fourth quartile compared with the lowest quartile. There
were no significant differences in MTV and TLG according to any
of the quartiles. Consequently, we dichotomised cfDNA by the
75th percentile, and MTV and TLG by the median.
As demonstrated in Figure 2, the median OS of patients with
cfDNA below the 75th percentile was 17.8 months (95% CI
13.0–24.5) compared with 8.8 months (95% CI 6.7–11.5) in
patients with cfDNA levels above the 75th percentile. The hazard
ratio (HR) was 2.05 (95% CI 0.94–4.50) with a P-value of 0.02.
Furthermore, high MTV was also associated with a shorter OS.
The OS of patients with MTV below the median was 21.9 months
(95% CI 13.0–26.9) compared with 7.0 months (95% CI 5.9–16.8)
in patients with MTV above the median (HR: 1.87 (95% CI
1.04–3.38), P¼ 0.02). There were no significant differences
according to the level of TLG (P¼ 0.08). The same applied to
PFS, with no significant differences according to any of the
parameters (data not shown).
Multivariate analysis. To investigate the independent prognostic
value of cfDNA and the PET parameters, multivariate Cox
regression analyses of OS were performed. Due to the low number
of events, only five parameters were included in the analyses.
The model is demonstrated in Table 2. In addition to cfDNA,
Table 1. Patient characteristics
Characteristic Number (n¼53) Percent (100)
Age
Median (range) 66 (47–80)
Gender
Male 25 47
Female 28 53
Histology
Adenocarcinoma 33 62
Squamous cell carcinoma 19 36
Large cell carcinoma 0 0
Other 1 2
Stage
III 17 32
IV 36 68
Distant metastases (incl. brain)
Yes 26 49
No 27 51
ECOG PS at baseline
0 20 38
1 29 55
2 4 7
Number of cycles
Median (range) 4 (1–6)
Abbreviation: ECOG PS¼Eastern Cooperative Oncology Group Performance Status.
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Figure 1. Correlation between the level of cfDNA and PET
parameters. (A) cfDNA and MTV: correlation coefficient (r)¼ 0.1.
(B) cfDNA and TLG: correlation coefficient (r)¼ 0.1.
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MTV and TLG, the well-documented prognostic parameters stage
and PS were included. As demonstrated in Table 2, cfDNA
dichotomised by the 75th percentile remained the only indepen-
dent prognostic marker with a risk ratio (RR) of 2.0 (95% CI
1.0–3.9, P¼ 0.04).
DISCUSSION
New biomarkers rank high in the development of new treatment
strategies in cancer. Although major efforts are made in studies of
different biomarkers, many challenges remain to identify clinically
reliable and hence useful biomarkers. Beyond the question of the
clinical applicability, the underlying biology with its enormous
molecular complexity remains obscure. Many studies in different
types of cancer have demonstrated a significant prognostic value of
the quantification of cfDNA, leading to the question of whether
cfDNA is merely a complicated way of measuring the tumour
burden. Since the biological mechanisms behind the presence of
cfDNA in the circulation remain insufficiently elucidated, the
question appears to be highly relevant.
Potential sources of cfDNA are discussed by Stroun et al who
find it little plausible that the primary source of cfDNA should be
circulating tumour cells or micro-metastases, as the number of
these is too low to provide larger amounts of cfDNA. Also, necrosis
from tumour cells is discussed but is probably insufficient to
entirely explain the increased levels observed with even small
tumours. The most plausible sources of cfDNA are apoptosis or
active release, which are mechanisms that may differ from tumour
to tumour without being dependent on tumour size (Stroun et al,
2000). Another source of cfDNA may be the necrosis of normal
tissue caused by the infiltrating tumour cells. This characteristic
may be more pronounced in the most aggressive tumours and add
explanation to the prognostic importance of cfDNA.
It is well known that cfDNA is also present in the circulation
during normal conditions, probably released from normal tissue
cells as well as from leukocytes and other cells undergoing lysis in
the blood stream. When investigating the total amount of cfDNA
in patients with malignant diseases, the risk of lysis caused by
prolonged stasis during blood sampling is thus important to be
aware of, as it may confound the results of the measurements.
Furthermore, the risk of contaminating the plasma with leukocytes
during the pipetting process should be accounted for as well as the
effect of different methods in plasma separation by centrifugation
may have on the final level of cfDNA in the sample. In our study,
plasma was separated by centrifugation at 2000 g for 10min, and it
may be discussed whether this approach is the best, or whether a
second centrifugation would have improved the separation as
described by Messauodi et al (2013). Also, we did not have the
possibility of detecting possible leukocyte contamination, but in a
previous study by Spindler et al (2012) using the same method,
a high correlation between the level of cfDNA and plasma mutated,
thus tumour-specific DNA was observed, supporting the reliability
of our method.
There is no gold standard for evaluation of tumour burden, but
PET/CT scans offer a fairly good instrument. Moreover, PET/CT
provides information on the metabolic activity, which may serve as a
marker of tumour aggressiveness. When estimating the tumour
volume by PET/CT it is, however, important to be aware of potential
sources of bias. A small number of lung tumours do not present
increased FDG uptake, for example, some bronchoalveolar carcino-
mas, carcinoids and small lesions and their lack of activity at the
PET/CT scan may lead to an underestimation of the true tumour
volume. Furthermore, to distinguish between inflamed and infected
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Figure 2. OS according to the level of cfDNA, MTV and TLG. (A) Dashed line: o75%, solid line: 475%, (B and C); dashed line: o50%,
Solid line: 450%. (A) OS according to cfDNA, median OS: o75%: 17.8 (13–24.5) and 475%: 8.8 (6.7–11.5); HR: 2.05 (95% CI 0.94–4.5);
P¼0.02. (B) OS according to MTV, median OS: o50%: 21.9 (13.0–26.9) and 450%: 7.0 (5.9–16.8); HR: 1.87 (95% CI 1.04–3.38); P¼ 0.02.
(C) OS according to TLG, median OS: o50%: 20.9 (12.4–25.5) and 450%: 8.8 (6.1–17.2); HR: 1.61 (95% CI 0.9–2.88); P¼0.08.
Table 2. Multivariate analyses of OS
OS
Variables Risk ratio (95% CI) P-value
Plasma cfDNA
o75%a
475%
2.0
(1.0–3.9)
0.04
MTV
oMediana
4Median
7.1
(0.5–98.8)
0.1
TLG
oMediana
4Median
0.2
(0.02–3.4)
0.3
PS
0-1a
2
1.1
(0.3–3.8)
0.9
Stage
3a
4
0.9
(0.5–1.6)
0.7
Abbreviations: cfDNA, cell-free DNA; CI, confidence interval; MTV, metabolic tumour
volume; OS, overall survival; PS, performance status; TLG, total lesion glycolysis.
All variables were dichotomised. The risk ratio refers to moving from the reference group to
the other group.
aReference group.
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areas of atelectasis and tumour may be difficult conferring potential
overestimation of the tumour burden. Metastases of the liver and
brain may also be difficult to evaluate due to high physiological
uptake in these organs. Specialist experience is therefore of utmost
importance when evaluating the scans and consequently, the PET/CT
scans in our study were evaluated by an experienced specialist of
nuclear medicine blinded to the level of cfDNA.
There is no overall consensus as to which index is more
appropriate for characterisation of tumour metabolism and
tumour volume from FDG PET. Several methods of measuring
MTV and TLG have been proposed. Some software use spatial
derivatives to locate tumour boundaries (Lee et al 2007; Zaizen
et al, 2012; Zhang et al, 2012), some use mediastinal background
þ 2s.d. as a reference (Chen et al, 2012), others use a cutoff at 50%
of SUVmax (Gould et al, 2001; Kim et al, 2012), and finally some
use a fixed cutoff value of 2.5 SUV (Liao et al, 2012; Hyun et al,
2013) as presented in this study. The latter method has been
quoted in textbooks for more than a decade (Hsu et al, 2003; Lin,
2009), is simple, and does not require reference values decreasing
the inter-observer variation. It is a pure metabolic measurement
without spatial delineation.
Our study is one of the first to examine the correlation between
cfDNA and tumour burden in terms of PET parameters. In a pilot
study by Kwee et al (2012), the correlation between cfDNA and
PET parameters during chemotherapy treatment of hormone-
refractory prostate cancer was described. Under the hypothesis that
the level of cfDNA increases due to chemotherapy-induced tumour
lysis, the level of cfDNA was correlated with the mean of all lesions
SUVmax. Thus, the metabolic activity and not the tumour burden
was the target of interest. The study included eight patients, and
some correlation between the levels of cfDNA, which indeed did
increase after chemotherapy, and the SUVmax was observed. Also,
patients with the lowest level of pre-treatment cfDNA were those
with the best treatment response. The study is interesting, but the
limited number of patients makes definite conclusions precarious.
Furthermore, the different design, tracer (18F-Fluorocholine) and
patient group, makes a full comparison with our results difficult.
We found no correlation between the PET parameters and cfDNA,
neither when considered as tumour burden by MTV nor as tumour
metabolic activity. There may be several explanations, including
cfDNA not merely reflecting the tumour burden, but being a
consequence of far more complicated biological mechanisms
remaining to be fully understood. We estimated tumour activity
by TLG, but did not find any correlation between the level of
cfDNA and this parameter. This may be due to the fact that TLG is
a combined measure of tumour volume and metabolic activity
estimated by SUV. The correlation between MTV and TLG was
almost perfect, making the observation of no correlations among
MTV, TLG and cfDNA little surprising.
The prognostic value of cfDNA and the PET parameters has
previously been reported in various studies (Lee et al, 2007; Chen
et al, 2012; Kim et al, 2012; Liao et al, 2012; Zaizen et al, 2012;
Zhang et al, 2012, 2013; Hyun et al, 2013). Some of the studies are
pre-surgical (Kim et al, 2012; Hyun et al, 2013; Zhang et al, 2013),
others are non-surgical (Liao et al, 2012; Zaizen et al, 2012), and
some include both NSCLC and SCLC (Lee et al, 2007). Most
studies are retrospective, and in some cases the number of patients
is low. The data are thus still sparse and require confirmation
in large, methodologically uniform studies. In our study, we
demonstrated a significantly shorter OS of patients with either
cfDNA above the 75th percentile or MTV above the median, which
is in accordance with a previous study by Zhang et al (2012). When
performing a multivariate analysis including both parameters, the
only one remaining statistically and independently significant was
cfDNA. This indication of a stronger prognostic value of cfDNA
than MTV supports the possible role of cfDNA as an independent
prognostic marker of clinical interest.
Even though our study is one of the first in this area and
strengthened by the prospective approach and independent PET
evaluation, the number of patients is limited, making definite
conclusions difficult. The lack of correlation between cfDNA and
tumour burden supports the argument that cfDNA is a
phenomenon beyond simple tumour lysis that may reflect more
complex biological mechanisms. Further studies of the biological
mechanisms behind the origin of cfDNA are called for.
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